Last updated: June 9, 2026
MIGERGOT drug suppliers: who manufactures, supplies, and distributes the pharmaceutical product
MIGERGOT supply in the U.S. market is driven by the branded product’s FDA approval holder and the companies listed on the label and drug product registrations. Without the drug’s specific FDA label, NDC strength/form, and the exact market (country), supplier identification cannot be stated accurately.
Which companies supply MIGERGOT to pharmacies and hospitals?
No complete supplier roster can be produced from the information provided. MIGERGOT can refer to different brand presentations and markets, and “supplier” can mean any of the following: marketing authorization holder, NDA/BLA holder, drug product manufacturer, repackager, or wholesale distributor.
What counts as a “supplier” for MIGERGOT in the supply chain?
- Marketing Authorization Holder / NDA Holder (regulatory responsibility)
- Drug Product Manufacturer (site that manufactures the finished product)
- Labeler / Repackager (entity tied to the NDC)
- Wholesale Distributor (distribution network to pharmacies/hospitals)
What active ingredient and dosage form does MIGERGOT contain?
No accurate ingredient-to-supplier mapping is possible without the specific MIGERGOT strength and dosage form (for example, tablets vs. injectables vs. oral formulations). Supplier identification depends on the exact product listing and NDC.
Does MIGERGOT differ by strength or dosage form in supplier listings?
Yes. Manufacturing sites and labelers often vary by strength, formulation, and packaging configuration.
What is the Orange Book status of MIGERGOT and how does that define suppliers?
A supplier list tied to regulatory status requires access to the FDA Orange Book record for the exact active ingredient and product presentation. Without that, the Orange Book entry cannot be matched to a specific labeler and manufacturing site set.
What supplier roles are reflected in Orange Book and FDA labeling?
- Patent holder and reference listed drug (RLD) mapping
- Marketing status (active, discontinued)
- Approved dosage forms and strengths
- Product/manufacturing information as listed with FDA submissions and labeling
Who manufactures MIGERGOT’s drug substance vs. finished drug product?
Finished-product manufacturers and drug-substance suppliers are not the same entity in many product supply chains. MIGERGOT’s contract manufacturing and API sourcing can differ across markets and years.
Can API suppliers be inferred from the brand name?
No. API sourcing is not reliably inferred from the brand name alone; it requires the exact product label and FDA submissions or CGMP registration links.
Which wholesalers distribute MIGERGOT at launch and during shortages?
Shortage-era distributor behavior changes by market and by time. Without a specific country and product presentation, no accurate wholesale distribution roster can be provided.
Do distribution suppliers differ from manufacturing suppliers?
Yes. Wholesalers are often separate from the manufacturer and can change due to logistics contracts and inventory routing.
How do generic or parallel suppliers affect MIGERGOT supply availability?
If generic competition exists, wholesale availability and labeler/manufacturer composition can shift quickly. No generic landscape can be stated without the exact drug identity and FDA listing.
Key Takeaways
- MIGERGOT supplier identification requires the exact MIGERGOT FDA/market product presentation (strength, dosage form, country) to map labeler, manufacturer sites, and distributors.
- The information provided does not include the data needed to produce a correct supplier list.
FAQs
- Is MIGERGOT manufactured by the same company that markets it?
- How can I identify the drug product manufacturer behind a specific MIGERGOT NDC?
- Do MIGERGOT suppliers change by strength or packaging size?
- Who supplies MIGERGOT during FDA shortages, and how is allocation handled?
- Does Orange Book status for MIGERGOT determine which generic suppliers can enter?
References (APA)
- FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
